Stock STABL STAYBLE THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Stayble Therapeutics AB

Equities

STABL

SE0013513652

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 16:20:18 15/05/2024 BST 		5-day change 1st Jan Change
0.2705 SEK +13.89% Intraday chart for Stayble Therapeutics AB +2.08% -10.73%
02-20 Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
2023 Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 68.2 87.51 55.39 9.611
Enterprise Value (EV) 1 58.37 50.9 43.39 -3.618
P/E ratio -4.41 x -7.24 x -2.26 x -0.33 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF -3,223,709 x -10,003,651 x -2,762,446 x 240,832 x
FCF Yield -0% -0% -0% 0%
Price to Book 4.39 x 2.2 x 3.62 x 0.58 x
Nbr of stocks (in thousands) 6,916 13,847 13,847 31,721
Reference price 2 9.860 6.320 4.000 0.3030
Announcement Date 03/05/21 02/05/22 09/05/23 17/04/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 0.5379 - - - -
EBITDA - - - - - -
EBIT 1 -6.117 -6.872 -14.98 -12.14 -24.95 -24
Operating Margin - -1,277.53% - - - -
Earnings before Tax (EBT) 1 -6.134 -7.408 -15.49 -12.09 -24.53 -23.74
Net income 1 -6.134 -7.408 -15.49 -12.09 -24.53 -23.74
Net margin - -1,377.25% - - - -
EPS - -1.822 -2.237 -0.8731 -1.771 -0.9214
Free Cash Flow - 3.068 -18.11 -5.088 -15.71 -15.02
FCF margin - 570.45% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18/03/19 21/04/20 03/05/21 02/05/22 09/05/23 17/04/24
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2.18 2.47 9.82 36.6 12 13.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 3.07 -18.1 -5.09 -15.7 -15
ROE (net income / shareholders' equity) -79.9% -217% -203% -43.7% -89% -149%
ROA (Net income/ Total Assets) -41.4% -45.9% -67.6% -24.6% -49.7% -73.4%
Assets 1 14.81 16.15 22.92 49.11 49.37 32.32
Book Value Per Share - -0.0700 2.250 2.870 1.100 0.5200
Cash Flow per Share - 0.9400 1.570 2.710 0.9300 0.4400
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 18/03/19 21/04/20 03/05/21 02/05/22 09/05/23 17/04/24
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
STAYBLE THERAPEUTICS AB Stock Stayble Therapeutics AB
-10.73% 696K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
BIONTECH SE Stock BioNTech SE
-12.64% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.95% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. STABL Stock
  4. Financials Stayble Therapeutics AB